Serrapeptamed

Serrapeptamed, licence 80069735: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names: Inflamed +, Rehab, Traumaforte, Traumamed
Licence holder: Les Importations Herbasanté Inc.
NPN or DIN-HM: 80069735
Status: Active licence
Licence date: 27 May 2016
Revision date: 17 February 2023
Form: Capsule
Route of administration: Orale
Application type: Non traditionnelle

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and source	Per dosage unit, according to the source	Maximum per day, adult
Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Partially hydrolysed chicken eggshell membrane	166.6 mg	Not calculated
Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Gallus gallus - Coquille d'oeuf	166.6 mg	Not calculated
Curcuma longa Source : Rhizome Potency : 22.0 % Curcuminoids	340.0 mg	Not calculated
Bromélaïne de fruit Source : Ananas comosus var. comosus - fruit	20400.0 FCC PU	Not calculated
Bromélaïne de fruit Source : Ananas comosus var. comosus - fruit	100.0 mg	Not calculated
Serrapeptase Source : Serratia - Cellule entière	40000.0 SPU	Not calculated
Serrapeptase Source : Serratia - Cellule entière	20.0 mg	Not calculated
Harpagophytum procumbens Source : Racine(s) secondaire(s) tubérisée(s) Extract : Matériel brut sec Extraction ratio : 2:1 Dry plant equivalent : 300 mg	150.0 mg	Not calculated

Non-medicinal ingredients

Hydroxypropyl méthylcellulose, Stéarate de magnésium

Recommended doses in Canada

Population	Age	Quantity per serving	Frequency
Adultes	Not specified	3.0 Capsule	1.0 Tous les jours

Uses authorised in Canada

Contains serrapeptidase, a Proteolytic Enzyme. Helps reduce and/or relieve postoperative cheek swelling and/or pain after dental surgery. Contains bromelain, a Digestive enzyme. Helps to reduce joint pain and reduce stiffness. Clinically proven to help reduce joint pain in 7-10 days. Used in Herbal Medicine as an anti-inflammatory to help relieve joint pain. Used in Herbal Medicine to help relieve joint pain associated with osteoarthritis. NEM® increases joint flexibility. NEM® helps reduce joint pain and stiffness. NEM® helps to relieve joint pain and stiffness associated with osteoarthritis (of the knee). NEM® is clinically proven to reduce joint pain in 7 to 10 days. NEM® helps to minimize discomfort due to moderate intensity aerobic exercise in post-menopausal women. NEM® helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise in post-menopausal women. NEM® helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise in post-menopausal women. NEM® helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise in post-menopausal women. NEM® helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day). NEM® starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. NEM® is clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days). NEM® helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise. NEM® helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise. NEM® helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. If you have a gastrointestinal lesion/ulcer, are taking anticoagulant/blood thinner or anti-inflammatory medication, or are having surgery, consult a health care practitioner prior to use. If you have a gastrointestinal lesion/ ulcer, are taking an anticoagulant/ blood thinner, anti-inflammatory or antibiotic, or are having surgery, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have gallstones or a bile duct obstruction. Consult a health care practitioner prior to use if you have stomach ulcers or excess stomach acid.
Effets indésirables connus
Hypersensitivity/allergy has been known to occur; in which case, discontinue use. Nausea, vomiting, and diarrhoea have been known to occur, in which case discontinue use (and consult a health care practitioner).

Source

Official Health Canada record, licence 80069735

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated 17 February 2023 (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2023. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.